GlassScriptPhysician profile
Jitender K Jain
NPI 1598784100
$5,388.87
in general payments reported to CMS, 2019-2025
43 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $317 · 2021: $645 · 2022: $690 · 2023: $936 · 2024: $895 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027 · Education: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.96 |
| Education | $805.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $770.88 | 2019-2025 | Jakafi, Niktimvo |
| Janssen Biotech, INC. | $600.61 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Sobi, INC | $535.76 | 2022-2025 | |
| Celgene Corporation | $327.69 | 2019-2024 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $308.23 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $213.38 | 2020-2024 | Keytruda, Lynparza |
| Amgen INC. | $203.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.20 | 2021-2023 | Ninlaro |
| Glaxosmithkline, LLC. | $198.15 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Legend Biotech USA INC. | $182.37 | 2024-2025 | Carvykti |
| Astellas Pharma US INC | $136.91 | 2022 | |
| Eisai INC. | $119.63 | 2019-2023 | |
| Coherus Oncology, INC. | $117.90 | 2021-2023 | |
| Amag Pharmaceuticals, INC. | $100.56 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $99.61 | 2022-2025 | Trelstar |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitender Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.